Becton Dickinson ramps upsyringe production amid demanddriven by China quality concerns

Becton Dickinson ramps upsyringe production amid demanddriven by China quality concerns

BD’s North Canaan plant has increased its output of syringes by more than 40% to meet the needs of U.S. healthcare customers after the FDA launched an ongoing investigation into quality issues with plastic syringes made in China.

Provided

NORTH CANAAN, Conn. — Becton, Dickinson and Company (BD) has ramped up its production of syringes at its North Canaan plant in response to quality issues with plastic syringes imported from China which were uncovered late last year by the U.S. Food and Drug Administration (FDA).

BD, a leading global medical technology company and Northwest Connecticut’s largest employer, responded to the FDA’s recommendation that consumers, healthcare providers and healthcare facilities transition away from plastic syringes made in China by increasing its domestic manufacturing of syringes at the company’s Connecticut and Nebraska facilities.

Since January, BD’s 385,000-square-foot North Canaan plant has increased its output of syringes “by over 40% to meet the needs of U.S. healthcare customers,” according to Fallon McLoughlin, director of public relations and corporate communications for the Franklin Lakes, N.J.-based company.

“BD has achieved this increase by driving operational efficiencies and relocating some production lines from other BD plants,” said McLoughin.

“We’ve added over 100 full-time associates in the last year, and currently have more than 500 full-time associates and nearly 50 contingent associates,” she said of the North Canaan site, which began its operations in 1961 with eight employees at a 25,000-square-foot facility.

BD draws its employees from throughout Northwest Connecticut and neighboring New York.

McLaughlin noted that its Connecticut plant primarily manufactures small-size syringes, and syringe and needle combination products that are “critical to the delivery of healthcare.”

Operations take place around the clock, producing more than 2 billion medical devices each year that are sold in every region worldwide.

Responding to consumer needs

In March, Eric Borin, president of BD Medication Delivery Solutions, announced a statement saying: “BD has the capacity to support additional syringe demand and is further increasing U.S. production to help ensure continuity of patient care.”

Since the initial FDA safety communication in November 2023, he noted, “BD has increased domestic manufacturing of syringes in our Nebraska and Connecticut facilities to respond to customer needs. Ensuring the safety and quality of our products is the top priority at BD.”

Borin further noted at the time that “The latest FDA safety communication does not include any BD syringes. Over our more than 125-year history, we have served the health care system’s need for essential high quality medical products, including manufacturing 2 billion additional syringes and needles to support the global pandemic response to COVID-19.”

Syringe manufacturers in China cited

In late November 2023, the FDA announced its probe into reports of leaks, breakages and other quality problems with plastic syringes manufactured in China “that are used for injecting fluids into or withdrawing fluids from, the body,” according to the health regulator.

On March 14, the FDA issued an update on warning letters sent to three entities: Jiangsu Shenli Medical Production Co. Ltd, Medline Industries, LP and Sol-Millennium Medical Inc., describing violations related to the “sale and distribution of unauthorized plastic syringes that had not been cleared or approved by the FDA,” according to a new release.

“In addition, we are actively evaluating quality issues and performance testing failures with plastic syringes made by Jiangsu Caina Medical Co Ltd., a China-based manufacturer sited in the warning letter issued to Medline Industries, LP. The FDA will take additional steps as appropriate,” the FDA stated.

In its August 16 update, the FDA continued to recommend that healthcare providers “use syringes not manufactured in China, if possible.

“At this time, glass syringes, pre-filled syringes or syringes used for topical purposes are not included. If you only have syringes manufactured in China, then continue to use them as needed until you are able to use alternative syringes and closely monitor for leaks, breakage and other problems,” the FDA announced.

In March, BD was named to Fortune’s 2024 list of America’s Most Innovative Companies, and in September, the company announced that it had been named to TIME’s 2024 list of the World’s Best Companies based on employee feedback.

BD’s operations in North Canaan have also been recognized by the U.S. Environmental Protection Agency for achieving the Energy Star Challenge for Industry for energy reduction. The site is a landfill-free site where waste is reduced, recycled or converted into energy.

Latest News

Millerton’s 175th committee advances plans for celebration, seeks vendors and sponsors

The Millerton 175th anniversary committee's tent during the village's trunk-or-treat event on Oct. 31, 2025.

Photo provided

MILLERTON — As Millerton officially enters its 175th year, the volunteer committee tasked with planning its milestone celebration is advancing plans and firming up its week-long schedule of events, which will include a large community fair at Eddie Collins Memorial Park and a drone light show. The events will take place this July 11 through 19.

Millerton’s 175th committee chair Lisa Hermann said she is excited for this next phase of planning.

Keep ReadingShow less
Why the focus on Greenland?

As I noted here in an article last spring entitled “Hands off Greenland”, the world’s largest island was at the center of a developing controversy. President Trump was telling all who would listen that, for national security reasons, the United States needed to take over Greenland, amicably if possible or by force if necessary. While many were shocked by Trump’s imperialistic statements, most people, at least in this country, took his words as ill-considered bluster. But he kept telling questioners that he had to have Greenland (oftenechoing the former King of France, Louis XIV who famously said, “L’État c’est moi!”.

Since 1951, the U.S. has had a security agreement with Denmark giving it near total freedom to install and operate whatever military facilities it wanted on Greenland. At one point there were sixteen small bases across the island, now there’s only one. Denmark’s Prime Minister has told President Trump that the U.S. should feel free to expand its installations if needed. As climate change is starting to allow a future passage from thePacific Ocean to the Arctic, many countries are showing interest in Greenland including Russia and China but this hardly indicates an international crisis as Trump and his subordinates insist.

Keep ReadingShow less
Military hardware as a signpost

It is hard not to equate military spending and purchasing with diplomatic or strategic plans being made, for reasons otherwise unknown. Keeping an eye out for the physical stuff can often begin to shine a light on what’s coming – good and possibly very bad.

Without Congressional specific approval, the Pentagon has awarded a contract to Boeing for $8,600,000,000 (US taxpayer dollars) for another 25 F-15A attack fighters to be given to Israel. Oh, and there’s another 25 more of the F-15EX variant on option, free to Israel as well.

Keep ReadingShow less
Truth and evidence depend on the right to observe

A small group of protesters voice opposition to President Trump's administration and Immigration and Customs Enforcement at Amenia's Fountain Square at the intersection of Route 44 and Route 22 on Saturday, Nov. 8, 2025

Photo by Nathan Miller

The fatal shooting of Alex Pretti, and before him Renée Good, by federal agents in Minnesota is not just a tragedy; it is a warning. In the aftermath, Trump administration officials released an account of events that directly contradicted citizen video recorded at the scene. Those recordings, made by ordinary people exercising their rights, showed circumstances sharply at odds with the official narrative. Once again, the public is asked to choose between the administration’s version of events and the evidence of its own eyes.

This moment underscores an essential truth: the right to record law enforcement is not a nuisance or a provocation; it is a safeguard. As New York Times columnist David French put it, “Citizen video has decisively rebutted the administration’s lies. The evidence of our eyes contradicts the dishonesty of the administration’s words.”

Keep ReadingShow less